R1 Rating RCM (NASDAQ:RCM) Reiterated by Cantor Fitzgerald

R1 RCM (NASDAQ:RCM – Get a Free Report)Its stock had a “neutral” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $14.30 price target on the healthcare provider’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 1.71% from the company’s current price.

RCM has been the subject of several other research reports. Leerink Partners cut shares of R1 RCM from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley cut shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Truist Financial dropped their price objective on shares of R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a research note on Thursday, August 8th. Jefferies Financial Group cut shares of R1 RCM from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of R1 RCM in a research report on Monday, July 22nd. Thirteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, R1 RCM currently has an average rating of “Hold” and an average price target of $15.41.

Get the latest report on R1 RCM

R1 RCM trading up 0.3%

RCM opened at $14.06 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.79, and a quick ratio of 1.79. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $18.22. The firm has a market cap of $5.92 billion, a PE ratio of -175.75 and a beta of 0.85. The company’s 50-day moving average is $12.96 and its 200-day moving average is $12.65.

R1 RCM (NASDAQ:RCM – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $627.90 million during the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The company’s revenue for the quarter was up 12.0% year-over-year. As a group, research analysts predict that R1 RCM will post -0.2 earnings per share for the current fiscal year.

Institutional inputs and outputs

Several institutional investors and hedge funds have recently bought and sold shares of RCM. Norges Bank bought a new position in R1 RCM in the 4th quarter valued at about $42,539,000. P2 Capital Partners LLC boosted its stake in R1 RCM by 70,366.3% in the 4th quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock worth $37,368,000 after bought an additional 3,530,277 shares in the last quarter. Boston Partners raised its stake in R1 RCM by 4,976.6% in the first quarter. Boston Partners now owns 2,570,371 shares of the health services provider’s stock worth $32,784,000 after buying an additional 2,519,739 shares during the last quarter. Empyrean Capital Partners LP purchased a new stake in R1 RCM in the second quarter valued at approximately $26,376,000. Finally, Sea Cliff Partners Management LP acquired a new stake in R1 RCM in the 4th quarter valued at about $18,459,000. 61.10% of shares are held by institutional investors.

R1 RCM Company Profile

(Get a free report)

R1 RCM Inc provides technology-based solutions for the financial performance and patient experience of health systems, hospitals and physician groups. Provides operational partnerships/end-to-end solutions that manage multiple aspects of the revenue cycle to achieve financial leverage and revenue improvement for hospital and physician clients.

Read more

Get R1 RCM news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for R1 RCM and related companies with MarketBeat.com’s FREE daily email newsletter.